Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2010

View Archived Issues

Prophylactic, not therapeutic, CCR2 inhibition efficacious in choroidal neovascularization

Roflumilast reduces body weight and BMI in COPD and type 2 diabetes

Potent anti-inflammatory and immunosuppressive activity of DTCM-G supported by preclinical data

ML-3403 shows promise in mouse models of colitis and RA

DHMEQ improves colonic injury in experimental colitis

ABCB5 promising as new biomarker in retinoblastoma

Preclinical and clinical data presented on bronchodilator LAS-100977

Abbott discloses new cannabinoid CB2 receptor ligands

U.S. military researchers claim new antimalarial agents

Merck & Co. presents new somatostatin receptor sst3 antagonists

Sinapis Pharma secures financing for phase I methamphetamine trial

Optimer and Biocon sign manufacturing and supply agreement for fidaxomicin

Cellceutix signs agreements for Kevetrin phase I support

Sanofi-aventis and MIT's Center for Biomedical Innovation form strategic alliance

Valeant Pharmaceuticals finalizes acquisition of Aton Pharma

AcelRx reports on phase II trial of ARX-02 Sufentanil NanoTab

NormOxys begins phase I trial of allosteric hemoglobin effector OXY-111A

Patupilone does not meet primary endpoint in phase III trial in ovarian cancer

Galderma discloses new melanocortin MC1 receptor ligands

Cytokinetics opens phase IIa CK-2017357 trial in peripheral artery disease

Cethromycin shows preclinical efficacy against Plasmodium species

FDA clears Simplexa influenza A H1N1 (2009) test

Enrollment initiated in new phase III program of Lu-AA-21004 in MDD

New phase II trial to evaluate Reolysin plus gemcitabine in pancreatic cancer

FDA accepts filing of Horizon Pharma's NDA for Duexa

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026